SFA — Sopharma AD Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesConservativeMid CapTurnaround

Annual income statement for Sopharma AD, fiscal year end - December 31st, BGN millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,450	1,616	1,675	1,895	2,145
Cost of Revenue
Gross Profit	270	311	324	377	363
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,412	1,564	1,609	1,800	2,066
Operating Profit	38.5	51.6	66.3	94.8	78.5
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	31.4	97.6	85.1	111	91.1
Provision for Income Taxes
Net Income After Taxes	25.3	91.7	76.3	99.9	82.1
Minority Interest
Net Income Before Extraordinary Items
Net Income	29.8	89.5	71.1	96	77.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	29.8	89.5	71.1	96	77.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.3	0.553	0.76	0.749	0.49
Dividends per Share